论文部分内容阅读
慢心律(mexiletine)是一种新的抗心律失常药,其化学结构及对稳定细胞膜的作用与利多卡因相似,但优于利多卡因。因为它可在胃肠道吸收,排泄较慢,血浆半衰期长达11 h,口服和静脉给药均能有效地控制室性心律失常。作者为了评价口服慢心律和奎尼丁在抑制室性期前收缩(premature ventricular contractions,PVCs)的效能和安全性而进行单盲随机研究。本组共51例病人,研究时间≤12周,随机分为两
Mexiletine is a new anti-arrhythmic drug whose chemical structure and action on stable cell membranes are similar to lidocaine but superior to lidocaine. Because it can be absorbed in the gastrointestinal tract, excretion slower, plasma half-life of up to 11 h, oral and intravenous administration can effectively control ventricular arrhythmias. The authors conducted a single-blind randomized study to evaluate the efficacy and safety of oral slow heart rhythm and quinidine in inhibiting premature ventricular contractions (PVCs). A total of 51 patients in this group, study time ≤ 12 weeks, were randomly divided into two